ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Novavax, Takeda and Sanofi side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Novavax×Takeda×Sanofi×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

NovavaxTakedaSanofi
studies on the registry481,7542,425
open to participants now086105
phase 3 studies under way04461
reach primary completion within a year04766
programswith a study of their own in two years12581+12 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseNovavaxTakedaSanofi
Phase 100%

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%
28%
Phase 200%

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%

Sanofi: 25 of its 81 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. BLU-808phase 2

and 20 more — sign in to see them all

31%
Phase 300%

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%

Sanofi: 22 of its 81 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

27%
Approved, new studies

Novavax: 1 of its 1 programs at approved, new studies

  1. NVX-COV2705approved, new study
100%

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%

Sanofi: 11 of its 81 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Novavax0 readouts · 0 phase 3············
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
Sanofi30 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702
  5. BLU-808phase 2 · Dec 31 · NCT06931405

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Novavax

New programs 0

None

Reached a new phase 0

None

Study stopped 1

  • NVX-COV2705approved, new study · terminated Oct 23 · none of its studies left running“The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaning…” · NCT07086222

Primary completion later 0

None

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 15 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionNovavaxTakedaSanofi
Crohn Disease2 of 3 · compare here–

Takeda in Crohn Disease: 3 programs

  1. zasocitinibphase 3
  2. teduglutidephase 3
  3. ontamalimabphase 3

Their studies: Takeda’s studies of Crohn Disease in search

Sanofi in Crohn Disease: 3 programs

  1. duvakitugphase 3
  2. brivekimigphase 2
  3. balinatunfibphase 2

Their studies: Sanofi’s studies of Crohn Disease in search

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating2 of 3 · compare here–

Takeda in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 4 programs

  1. TAK-411phase 2
  2. Immunoglobulins, Intravenousapproved, new study
  3. Hyaluronoglucosaminidaseapproved, new study
  4. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Sanofi in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 1 program

  1. riliprubartphase 3

Their studies: Sanofi’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Colitis, Ulcerative2 of 3 · compare here–

Takeda in Colitis, Ulcerative: 1 program

  1. ontamalimabphase 3

Their studies: Takeda’s studies of Colitis, Ulcerative in search

Sanofi in Colitis, Ulcerative: 3 programs

  1. duvakitugphase 3
  2. brivekimigphase 2
  3. balinatunfibphase 2

Their studies: Sanofi’s studies of Colitis, Ulcerative in search

COVID-192 of 3 · compare here

Novavax in COVID-19: 1 program

  1. NVX-COV2705approved, new study

Their studies: Novavax’s studies of COVID-19 in search

–

Sanofi in COVID-19: 3 programs

  1. NVX-COV2705phase 3
  2. Biological Productsphase 1
  3. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study

Their studies: Sanofi’s studies of COVID-19 in search

Psoriasis2 of 3 · compare here–

Takeda in Psoriasis: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Psoriasis in search

Sanofi in Psoriasis: 3 programs

  1. balinatunfibphase 2
  2. belumosudilapproved, new study
  3. teplizumabapproved, new study

Their studies: Sanofi’s studies of Psoriasis in search

Purpura, Thrombocytopenic, Idiopathic2 of 3 · compare here–

Takeda in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. mezagitamabphase 3
  2. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Sanofi in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. rilzabrutinibphase 3
  2. riliprubartphase 3

Their studies: Sanofi’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Anemia, Sickle Cell2 of 3 · compare here–

Takeda in Anemia, Sickle Cell: 1 program

  1. apadamtase alfaphase 3

Their studies: Takeda’s studies of Anemia, Sickle Cell in search

Sanofi in Anemia, Sickle Cell: 2 programs

  1. rilzabrutinibphase 3
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3

Their studies: Sanofi’s studies of Anemia, Sickle Cell in search

Hemophilia A2 of 3 · compare here–

Takeda in Hemophilia A: 1 program

  1. antihemophilic factor, human recombinantapproved, new study

Their studies: Takeda’s studies of Hemophilia A in search

Sanofi in Hemophilia A: 2 programs

  1. fitusiranapproved, new study
  2. efanesoctocog alfaapproved, new study

Their studies: Sanofi’s studies of Hemophilia A in search

Hidradenitis Suppurativa2 of 3 · compare here–

Takeda in Hidradenitis Suppurativa: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Hidradenitis Suppurativa in search

Sanofi in Hidradenitis Suppurativa: 2 programs

  1. brivekimigphase 2
  2. zetrukibartphase 2

Their studies: Sanofi’s studies of Hidradenitis Suppurativa in search

Lupus Erythematosus, Systemic2 of 3 · compare here–

Takeda in Lupus Erythematosus, Systemic: 1 program

  1. mezagitamabphase 3

Their studies: Takeda’s studies of Lupus Erythematosus, Systemic in search

Sanofi in Lupus Erythematosus, Systemic: 2 programs

  1. frexalimabphase 3
  2. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lupus Erythematosus, Systemic in search

von Willebrand Diseases2 of 3 · compare here–

Takeda in von Willebrand Diseases: 2 programs

  1. vonicog alfaphase 3
  2. antihemophilic factor, human recombinantapproved, new study

Their studies: Takeda’s studies of von Willebrand Diseases in search

Sanofi in von Willebrand Diseases: 1 program

  1. efanesoctocog alfaapproved, new study

Their studies: Sanofi’s studies of von Willebrand Diseases in search

Alzheimer Disease2 of 3 · compare here–

Takeda in Alzheimer Disease: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Alzheimer Disease in search

Sanofi in Alzheimer Disease: 1 program

  1. SAR448851phase 2

Their studies: Sanofi’s studies of Alzheimer Disease in search

Show all 15

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Novavax 0 of 1 · Takeda 12 of 25 · Sanofi 54 of 81 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12).